"Although most do not expect biosimilars ...

... to mirror the generic market in price decrease, there is strong anticipation among payers that biosimilars will become a primary strategy to reduce specialty drug prices as 'lower-cost' branded options. Using the European market as a guide, payers are projecting pricing discounts within one to three years for biosimilar(s) and their originators of up to 20% to 30%. How large this discount turns out to be is dependent on the total market value that the biosimilar is competing in and the number of product competitors."

— Lynn Nishida, assistant vice president of pharmacy services at Solid Benefit Guidance, told AIS's Specialty Pharmacy News.